(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are BOQI International Medical, Citius Pharmaceuticals, and Brooge Energy Limited .

Rank Financial Asset Price Change Updated (EST)
1 BOQI International Medical (BIMI) 0.68 30.04% 2022-06-12 19:44:13
2 Citius Pharmaceuticals (CTXRW) 0.15 25% 2022-06-13 15:13:06
3 Brooge Energy Limited (BROGW) 0.36 9.61% 2022-06-12 23:10:06
4 BeyondSpring (BYSI) 1.77 3.51% 2022-06-13 03:23:15
5 Brookfield Residential Properties (BRP) 26.31 2.73% 2022-06-12 23:11:06
6 Biomerica (BMRA) 3.80 2.7% 2022-06-12 21:10:08
7 Merrimack Pharmaceuticals (MACK) 5.25 2.54% 2022-06-13 14:59:36
8 Cincinnati Bancorp (CNNB) 14.67 1.59% 2022-06-13 11:15:12
9 CME Group (CME) 202.99 1.55% 2022-06-13 14:56:24
10 Celcuity (CELC) 7.71 1.31% 2022-06-13 07:10:07

The three most active and biggest losers today are Check-Cap Ltd., BioCardia, and MicroStrategy.

Rank Financial Asset Price Change Updated (EST)
1 Check-Cap Ltd. (CHEKZ) 0.06 -29.25% 2022-06-13 07:43:15
2 BioCardia (BCDAW) 0.32 -29.12% 2022-06-12 19:06:10
3 MicroStrategy (MSTR) 152.03 -25.24% 2022-06-13 14:57:58
4 Blueprint Medicines Corporation (BPMC) 48.07 -18.21% 2022-06-12 22:41:14
5 Cyclerion Therapeutics (CYCN) 0.54 -17.92% 2022-06-13 15:49:14
6 Brilliant Acquisition Corporation (BRLIW) 0.08 -16.56% 2022-06-12 23:09:07
7 New Residential Investment (NRZ) 9.09 -16.42% 2022-06-13 14:47:41
8 DraftKings (DKNG) 11.07 -15.5% 2022-06-13 14:48:27
9 Clean Energy Fuels (CLNE) 4.82 -14.78% 2022-06-13 14:56:18
10 Berkeley Lights (BLI) 4.52 -13.41% 2022-06-12 20:23:14

Most Active Winners today

1. BOQI International Medical (BIMI) – 30.04%

BIMI International Medical Inc. and its affiliates are involved in retailing and wholesale distribution of medical equipment, pharmaceuticals, and other healthcare products within the People’s Republic of China. The company offers over-the-counter and prescription drugs as well as nutritional supplements, sundry products and traditional Chinese medicine. It also sells miscellaneous products under the Lijiantang Pharmacy name. It also offers IT research and development. The company sells medicine and other products directly to its customers. The former name of the company was BOQI International Medical Inc., but it changed its name in June 2021 to BIMI International Medical Inc. BIMI International Medical Inc. is a 2000 incorporation and has its headquarters in Dalian (the People’s Republic of China).

NASDAQ ended the session with BOQI International Medical jumping 30.04% to $0.68 on Monday, after three sequential sessions in a row of gains. NASDAQ slid 4.68% to $10,809.23, after three sequential sessions in a row of losses, on what was a very bearish trend exchanging session today.

Volume

Today’s last reported volume for BOQI International Medical is 29647300 which is 1809.94% above its average volume of 1552260.

BOQI International Medical’s last close was $0.68, 94.91% below its 52-week high of $13.35.

BOQI International Medical’s Stock Yearly Top and Bottom Value

BOQI International Medical’s stock is valued at $0.68 at 17:32 EST, way below its 52-week high of $13.35 and way higher than its 52-week low of $0.40.

BOQI International Medical’s Moving Average

BOQI International Medical’s value is way below its 50-day moving average of $0.85 and way under its 200-day moving average of $2.33.

More news about BOQI International Medical.

2. Citius Pharmaceuticals (CTXRW) – 25%

NASDAQ ended the session with Citius Pharmaceuticals jumping 25% to $0.15 on Monday, after five sequential sessions in a row of losses. NASDAQ fell 4.68% to $10,809.23, after three sequential sessions in a row of losses, on what was a very down trend exchanging session today.

Citius Pharmaceuticals’s last close was $0.13, 20.59% under its 52-week high of $0.16.

Citius Pharmaceuticals’s Stock Yearly Top and Bottom Value

Citius Pharmaceuticals’s stock is valued at $0.15 at 17:32 EST, below its 52-week high of $0.16 and above its 52-week low of $0.14.

More news about Citius Pharmaceuticals.

3. Brooge Energy Limited (BROGW) – 9.61%

NASDAQ ended the session with Brooge Energy Limited jumping 9.61% to $0.36 on Monday, after five successive sessions in a row of losses. NASDAQ slid 4.68% to $10,809.23, after three successive sessions in a row of losses, on what was a very down trend trading session today.

Brooge Energy Limited ‘s last close was $0.36, 2.98% below its 52-week high of $0.37.

Brooge Energy Limited ‘s Stock Yearly Top and Bottom Value

Brooge Energy Limited ‘s stock is valued at $0.36 at 17:32 EST, below its 52-week high of $0.37 and way higher than its 52-week low of $0.21.

More news about Brooge Energy Limited .

4. BeyondSpring (BYSI) – 3.51%

BeyondSpring Inc. is a biopharmaceutical company at the clinical stage. It works with its subsidiaries to develop and market immuno-oncology treatments for cancer. Plinabulin, an anti-cancer drug in combination with docetaxel (in advanced non-small-cell lung cancer), is currently in clinical trial. This is to prevent high- and intermediate-risk chemotherapy-induced neutropenia. Plinabulin is being developed in conjunction with other immuno-oncology drugs, such as nivolumab (a programmed cell-death protein 1 antibody) for treatment of NSCLC. The company is also developing three small-molecule immuno agents for preclinical testing. It has also developed a platform to develop drugs using the ubiquitin-mediated protein degradation pathway. BeyondSpring Inc. is a partner of the Fred Hutchinson Cancer Research Center, and University of Washington. New York is the headquarters of BeyondSpring Inc., which was established in 2010.

NASDAQ ended the session with BeyondSpring rising 3.51% to $1.77 on Monday while NASDAQ fell 4.68% to $10,809.23.

Volume

Today’s last reported volume for BeyondSpring is 333329 which is 6.3% below its average volume of 355750.

BeyondSpring’s last close was $1.77, 94.64% under its 52-week high of $33.00.

The company’s growth estimates for the present quarter and the next is 47.7% and 51%, respectively.

BeyondSpring’s Revenue

Year-on-year quarterly revenue growth grew by 87.8%, now sitting on 1.35M for the twelve trailing months.

BeyondSpring’s Stock Yearly Top and Bottom Value

BeyondSpring’s stock is valued at $1.77 at 17:32 EST, way under its 52-week high of $33.00 and way higher than its 52-week low of $1.13.

BeyondSpring’s Moving Average

BeyondSpring’s value is higher than its 50-day moving average of $1.73 and way below its 200-day moving average of $7.69.

More news about BeyondSpring.

5. Brookfield Residential Properties (BRP) – 2.73%

BRP Group, Inc. sells and markets insurance products in the United States. There are four main segments to the company: MainStreet (Middle Market), Specialty (MainStreet), and Medicare. The Middle Market segment offers private and commercial risk management and employee benefits for small and medium-sized businesses as well as high-net-worth individuals and their families. Specialty is a wholesale brokerage platform for programs that require underwriting or placement. MainStreet offers insurance for individuals, businesses, as well as life and health services to residents and business owners. Through a network, the Medicare segment offers assistance for seniors through government assistance programs. It was established in Tampa in 2011.

NASDAQ ended the session with Brookfield Residential Properties jumping 2.73% to $26.31 on Monday while NASDAQ fell 4.68% to $10,809.23.

Volume

Today’s last reported volume for Brookfield Residential Properties is 699462 which is 18.3% above its average volume of 591258.

Brookfield Residential Properties’s last close was $26.31, 42% under its 52-week high of $45.36.

The company’s growth estimates for the ongoing quarter and the next is 42.9% and 72.7%, respectively.

Brookfield Residential Properties’s Revenue

Year-on-year quarterly revenue growth grew by 58.9%, now sitting on 657.31M for the twelve trailing months.

Brookfield Residential Properties’s Stock Yearly Top and Bottom Value

Brookfield Residential Properties’s stock is valued at $26.31 at 17:32 EST, way under its 52-week high of $45.36 and way higher than its 52-week low of $17.08.

Brookfield Residential Properties’s Moving Average

Brookfield Residential Properties’s value is above its 50-day moving average of $24.33 and way below its 200-day moving average of $31.08.

More news about Brookfield Residential Properties.

6. Biomerica (BMRA) – 2.7%

Biomerica, Inc., is a biomedical tech company that develops, patents, produces, markets, and sells diagnostic and therapeutic products for the detection, treatment, or prevention of diseases and conditions. Diagnostic test kits from the company are used for the analysis of blood and urine samples of patients to diagnose various medical conditions and complications. They also measure specific bacteria, hormones and antibodies in blood and stool. The company sells products to treat gastrointestinal disorders, food intolerances and diabetes. It also offers a variety of esoteric testing at doctors’ offices, over-the-counter drugstores and hospitals/clinical labs. InFoods is a gastrointestinal therapy and diagnostic-guided treatment company. It develops Helicobacter Pylori products and tests and validates COVID-19 products. Biomerica, Inc., was established in 1971. It is located in Irvine, California.

NASDAQ ended the session with Biomerica rising 2.7% to $3.80 on Monday while NASDAQ fell 4.68% to $10,809.23.

Volume

Today’s last reported volume for Biomerica is 7670 which is 73.3% below its average volume of 28734.

Biomerica’s last close was $3.80, 48.51% below its 52-week high of $7.38.

Biomerica’s Revenue

Year-on-year quarterly revenue growth grew by 111.1%, now sitting on 14.62M for the twelve trailing months.

Biomerica’s Stock Yearly Top and Bottom Value

Biomerica’s stock is valued at $3.80 at 17:32 EST, way below its 52-week high of $7.38 and way above its 52-week low of $2.65.

Biomerica’s Moving Average

Biomerica’s value is higher than its 50-day moving average of $3.73 and way under its 200-day moving average of $4.30.

More news about Biomerica.

7. Merrimack Pharmaceuticals (MACK) – 2.54%

NASDAQ ended the session with Merrimack Pharmaceuticals rising 2.54% to $5.25 on Monday, following the last session’s upward trend. NASDAQ slid 4.68% to $10,809.23, after three successive sessions in a row of losses, on what was a very bearish trend exchanging session today.

Volume

Today’s last reported volume for Merrimack Pharmaceuticals is 17548 which is 10.54% above its average volume of 15874.

Merrimack Pharmaceuticals’s last close was $5.25, 29.15% below its 52-week high of $7.41.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Merrimack Pharmaceuticals’s stock is considered to be oversold (<=20).

Merrimack Pharmaceuticals’s Stock Yearly Top and Bottom Value

Merrimack Pharmaceuticals’s stock is valued at $5.25 at 17:32 EST, way below its 52-week high of $7.41 and way higher than its 52-week low of $3.66.

Merrimack Pharmaceuticals’s Moving Average

Merrimack Pharmaceuticals’s value is under its 50-day moving average of $5.62 and above its 200-day moving average of $5.08.

More news about Merrimack Pharmaceuticals.

8. Cincinnati Bancorp (CNNB) – 1.59%

Cincinnati Bancorp, Inc. is the holding company of Cincinnati Federal. It provides various financial and banking services to Americans and small businesses. You can open checking, savings or certificate deposit accounts. Its loan portfolio includes residential loans for one to four families, multi-family and nonresidential loans as well as home equity loans and credit lines, construction loans and land loans. The company also invests in mortgage-backed securities. The company has full-service branches in Miami Heights and Anderson in Ohio as well as Covington, Florence, and Florence, Northern Kentucky. It was established in Cincinnati, Ohio in 1922.

NASDAQ ended the session with Cincinnati Bancorp jumping 1.59% to $14.67 on Monday, following the last session’s upward trend. NASDAQ dropped 4.68% to $10,809.23, after three consecutive sessions in a row of losses, on what was a very negative trend trading session today.

Volume

Today’s last reported volume for Cincinnati Bancorp is 218 which is 90.69% below its average volume of 2344.

Cincinnati Bancorp’s last close was $14.67, 7.97% below its 52-week high of $15.94.

Cincinnati Bancorp’s Revenue

Year-on-year quarterly revenue growth declined by 32.6%, now sitting on 16.2M for the twelve trailing months.

Cincinnati Bancorp’s Stock Yearly Top and Bottom Value

Cincinnati Bancorp’s stock is valued at $14.67 at 17:32 EST, under its 52-week high of $15.94 and higher than its 52-week low of $13.75.

Cincinnati Bancorp’s Moving Average

Cincinnati Bancorp’s worth is below its 50-day moving average of $14.93 and below its 200-day moving average of $14.85.

More news about Cincinnati Bancorp.

9. CME Group (CME) – 1.55%

CME Group Inc. operates, via its subsidiaries, contract markets worldwide for futures trading and options on futures contracts. Futures and options products are offered based on interest rate, equity indexes or foreign exchange. It also offers fixed income products via its electronic trading platforms. Clearing for cleared swaps and exchange-traded contracts is also offered by the company. Settlement services are available as well. Transaction lifecycle management services include trade management and portfolio optimization as financial reporting and regulatory reporting. The company also offers market data services that include historical and real-time data. The company serves professionals traders, banks, individual and institutional investors, corporates, as well as manufacturers, suppliers, government officials, central banks, and producers. To develop risk management products that can be used by Brazilian market participants, the company is a strategic partner with B3 S.A. The original name of the company was Chicago Mercantile Exchange Holdings Inc., but it changed its name in July 2007 to CME Group Inc. CME Group Inc. was established in 1898. It is located in Chicago, Illinois.

NASDAQ ended the session with CME Group jumping 1.55% to $202.99 on Monday, following the last session’s upward trend. NASDAQ slid 4.68% to $10,809.23, after three consecutive sessions in a row of losses, on what was a very down trend exchanging session today.

Volume

Today’s last reported volume for CME Group is 2355010 which is 46.81% above its average volume of 1604010.

CME Group’s last close was $199.90, 22.2% under its 52-week high of $256.94.

The company’s growth estimates for the present quarter and the next is 15.9% and 21.9%, respectively.

CME Group’s Revenue

Year-on-year quarterly revenue growth grew by 7.7%, now sitting on 4.77B for the twelve trailing months.

CME Group’s Stock Yearly Top and Bottom Value

CME Group’s stock is valued at $202.99 at 17:32 EST, way under its 52-week high of $256.94 and above its 52-week low of $185.79.

CME Group’s Moving Average

CME Group’s value is below its 50-day moving average of $214.28 and below its 200-day moving average of $219.83.

More news about CME Group.

10. Celcuity (CELC) – 1.31%

Celcuity Inc. is a biotechnology company in clinical stages. It discovers sub-types of cancer and offers therapeutic options to patients with cancer. CELsignia’s diagnostic platform, which uses patient-derived tumor cells as a source of information to determine the abnormal cell process that is driving the patient’s disease and then prescribe targeted therapies. CELsignia MP, which is a laboratory-developed test measuring HER2, cMet and PI3K activity in breast tumor cells and ovarian cancer cells, has also been developed by the company. Celcuity Inc. is located in Minneapolis, Minnesota.

NASDAQ ended the session with Celcuity rising 1.31% to $7.71 on Monday, after two sequential sessions in a row of gains. NASDAQ fell 4.68% to $10,809.23, after three consecutive sessions in a row of losses, on what was a very down trend trading session today.

Volume

Today’s last reported volume for Celcuity is 50330 which is 34.36% below its average volume of 76682.

Celcuity’s last close was $7.71, 76.64% under its 52-week high of $33.01.

The company’s growth estimates for the present quarter and the next is 55% and 12.2%, respectively.

Celcuity’s Stock Yearly Top and Bottom Value

Celcuity’s stock is valued at $7.71 at 17:32 EST, way under its 52-week high of $33.01 and way above its 52-week low of $4.81.

Celcuity’s Moving Average

Celcuity’s value is higher than its 50-day moving average of $7.01 and way under its 200-day moving average of $12.61.

More news about Celcuity.

Most Active Losers Today

1. Check-Cap Ltd. (CHEKZ) – -29.25%

NASDAQ ended the session with Check-Cap Ltd. dropping 29.25% to $0.06 on Monday, after five successive sessions in a row of losses. NASDAQ dropped 4.68% to $10,809.23, after three consecutive sessions in a row of losses, on what was a very down trend exchanging session today.

Check-Cap Ltd.’s last close was $0.06, 45.45% under its 52-week high of $0.11.

Check-Cap Ltd.’s Stock Yearly Top and Bottom Value

Check-Cap Ltd.’s stock is valued at $0.06 at 17:32 EST, under its 52-week low of $0.06.

More news about Check-Cap Ltd..

2. BioCardia (BCDAW) – -29.12%

NASDAQ ended the session with BioCardia sliding 29.12% to $0.32 on Monday, after five consecutive sessions in a row of losses. NASDAQ fell 4.68% to $10,809.23, after three consecutive sessions in a row of losses, on what was a very down trend exchanging session today.

BioCardia’s last close was $0.32, 45.51% below its 52-week high of $0.59.

BioCardia’s Stock Yearly Top and Bottom Value

BioCardia’s stock is valued at $0.32 at 17:32 EST, below its 52-week low of $0.32.

More news about BioCardia.

3. MicroStrategy (MSTR) – -25.24%

MicroStrategy Incorporated offers enterprise analytics software and other services around the world. MicroStrategy 2020 is an enterprise platform that provides analytics across multiple devices. It allows analysts and data scientists seamless access to trust-governed data within their tool. MicroStrategy support is available to customers in order to help them achieve system availability, uptime and improve their overall user experience. This includes proactive product support and highly responsive technical troubleshooting. It also offers MicroStrategy Consulting, which provides architecture and implementation services that help customers quickly achieve results and maximize returns on their investment. It provides services via channel partners and enterprise sales. The company serves various industries including technology, retail, consulting and manufacturing. It also provides services through channel partners. It was established in Tysons Corner in Virginia in 1989.

NASDAQ ended the session with MicroStrategy falling 25.24% to $152.03 on Monday while NASDAQ fell 4.68% to $10,809.23.

Volume

Today’s last reported volume for MicroStrategy is 3564950 which is 384.11% above its average volume of 736382.

MicroStrategy’s last close was $203.36, 77.19% under its 52-week high of $891.38.

News about MicroStrategy today

  • According to today’s article on FXStreet, "The remaining approximately 115,100 Bitcoins are held at the MicroStrategy subsidiary. ", "Of the MicroStrategy of Bitcoins, approximately 19,500 Bitcoins are pledged ascollateral towardthe Bitcoin-backed term loan and over 95,600 Bitcoins remain unpledged and unencumbered." So it looks pretty safe to me from this viewpoint. "
  • Microstrategy stock falls 23% on Bitcoin plunge. According to today’s article on The Wall Street Journal, "Shares of MicroStrategy Inc. tumbled Monday as investors fretted over what a brutal selloff in cryptocurrencies would mean for the software company’s finances."

The company’s growth estimates for the current quarter and the next is a negative 36% and a negative 22%, respectively.

MicroStrategy’s Revenue

Year-on-year quarterly revenue growth grew by 2.4%, now sitting on 510.76M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

MicroStrategy’s stock is considered to be overbought (>=80).

MicroStrategy’s Stock Yearly Top and Bottom Value

MicroStrategy’s stock is valued at $152.03 at 17:33 EST, way under its 52-week high of $891.38 and way higher than its 52-week low of $134.09.

MicroStrategy’s Moving Average

MicroStrategy’s value is way below its 50-day moving average of $322.76 and way under its 200-day moving average of $511.87.

More news about MicroStrategy.

4. Blueprint Medicines Corporation (BPMC) – -18.21%

Blueprint Medicines Corporation is a precision-therapy company that develops drugs for cancer patients and other hematologic conditions. It also offers multiple programs to treat genomically determined cancers and systemic mastocytosis. The company has developed avapritinib to treat systemic mastocytosis and gastrointestinal stromal tumours. BLU-263 is an oral, potent and KIT inhibitor that can be used for treatment of advanced SM. Phase 1b/2 trials are underway for fisogatinib which is an orally accessible and powerful inhibitor. The company is currently developing pralsetinib to treat RET-altered small cell lung cancer and altered solid tumors. BLU-701, a selective inhibitor of double-mutant EGFR harboring and BLU-945 are also in the preclinical phase. The company also has BLU-782 in development, which is an oral and investigative activin-likekinase 2-inhibitor. This is currently being tested for fibrodysplasia progressive. Clementia Pharmaceuticals, Inc., CStone Pharmaceuticals, Genentech, Inc., and F. Hoffmann-La Roche Ltd. have collaborated and licensed the company. Blueprint Medicines Corporation was previously known as Hoyle Pharmaceutics, Inc. Blueprint Medicines Corporation was established in 2008. It is located in Cambridge, Massachusetts.

NASDAQ ended the session with Blueprint Medicines Corporation dropping 18.21% to $48.07 on Monday, after two consecutive sessions in a row of losses. NASDAQ dropped 4.68% to $10,809.23, after three sequential sessions in a row of losses, on what was a very bearish trend trading session today.

Volume

Today’s last reported volume for Blueprint Medicines Corporation is 3795580 which is 447.6% above its average volume of 693122.

Blueprint Medicines Corporation’s last close was $48.07, 59.21% under its 52-week high of $117.86.

Blueprint Medicines Corporation’s Sales

Blueprint Medicines Corporation’s sales growth is 90.8% for the present quarter and 2% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 19.4% and a negative 8.5%, respectively.

Blueprint Medicines Corporation’s Revenue

Year-on-year quarterly revenue growth grew by 213.8%, now sitting on 180.08M for the twelve trailing months.

Blueprint Medicines Corporation’s Stock Yearly Top and Bottom Value

Blueprint Medicines Corporation’s stock is valued at $48.07 at 17:33 EST, way under its 52-week high of $117.86 and above its 52-week low of $47.71.

Blueprint Medicines Corporation’s Moving Average

Blueprint Medicines Corporation’s value is way below its 50-day moving average of $60.56 and way under its 200-day moving average of $83.13.

More news about Blueprint Medicines Corporation.

5. Cyclerion Therapeutics (CYCN) – -17.92%

Cyclerion Therapeutics, Inc. is a biopharmaceutical company at clinical stage. It focuses on the discovery, development, commercialization, and marketing of medications for severe central nervous system diseases. Its products include CY6463 (a CNS-penetrant soluble guanylate cyclase [sGC] stimulator) that is currently in Phase II trials to treat mitochondrial encephalomyopathy and lactic acidosis (MELAS), and Alzheimer’s Disease with vascular pathology. Olinciguat (orally administered vascular soluble guanylate cyclase stimulation stimulator) that is being studied in Phase II for treatment of sickle cells disease (SGC stimulator) that can be taken orally. It was founded in 2018, and its headquarters are in Cambridge, Massachusetts.

NASDAQ ended the session with Cyclerion Therapeutics sliding 17.92% to $0.54 on Monday, following the last session’s downward trend. NASDAQ fell 4.68% to $10,809.23, after three consecutive sessions in a row of losses, on what was a very down trend exchanging session today.

Volume

Today’s last reported volume for Cyclerion Therapeutics is 493375 which is 143.23% above its average volume of 202842.

Cyclerion Therapeutics’s last close was $0.66, 86.46% under its 52-week high of $4.86.

The company’s growth estimates for the present quarter is 44.4% and a drop 23.1% for the next.

Cyclerion Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 300.8%, now sitting on 3.94M for the twelve trailing months.

Cyclerion Therapeutics’s Stock Yearly Top and Bottom Value

Cyclerion Therapeutics’s stock is valued at $0.54 at 17:33 EST, way below its 52-week high of $4.86 and higher than its 52-week low of $0.50.

Cyclerion Therapeutics’s Moving Average

Cyclerion Therapeutics’s value is way under its 50-day moving average of $0.77 and way below its 200-day moving average of $1.72.

More news about Cyclerion Therapeutics.

6. Brilliant Acquisition Corporation (BRLIW) – -16.56%

NASDAQ ended the session with Brilliant Acquisition Corporation falling 16.56% to $0.08 on Monday, after five successive sessions in a row of losses. NASDAQ fell 4.68% to $10,809.23, after three consecutive sessions in a row of losses, on what was a very negative trend trading session today.

Brilliant Acquisition Corporation’s last close was $0.08, 16.56% below its 52-week high of $0.09.

Brilliant Acquisition Corporation’s Stock Yearly Top and Bottom Value

Brilliant Acquisition Corporation’s stock is valued at $0.08 at 17:33 EST, way below its 52-week high of $0.09 and above its 52-week low of $0.08.

More news about Brilliant Acquisition Corporation.

7. New Residential Investment (NRZ) – -16.42%

New Residential Investment Corp. is a trust that invests in residential mortgage assets and manages them. The company operates in four segments: Origination, Servicing, MSR Related Investments, Residential Securities and Loans, Consumer Loans, and Servicing. It invests in residential mortgage servicing rights (MSRs), and servicer advances. This includes the basic fee portion of MSRs. The company also invests on real estate and in residential mortgage loans. For federal income tax purposes, the company is a real-estate investment trust. If it pays at least 90% of its income, the company is not subject to federal corporate income tax. It was established in New York in 2011.

NYSE ended the session with New Residential Investment falling 16.42% to $9.09 on Monday, after five sequential sessions in a row of losses. NYSE fell 3.77% to $14,527.90, after three consecutive sessions in a row of losses, on what was a very bearish trend trading session today.

Volume

Today’s last reported volume for New Residential Investment is 21228000 which is 282.87% above its average volume of 5544300.

New Residential Investment’s last close was $10.87, 7.96% below its 52-week high of $11.81.

New Residential Investment’s Sales

New Residential Investment’s sales growth is a negative 5.3% for the ongoing quarter and 31.5% for the next. The company’s growth estimates for the current quarter is 19.4% and a drop 15.9% for the next.

New Residential Investment’s Revenue

Year-on-year quarterly revenue growth grew by 153.8%, now sitting on 3.01B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

New Residential Investment’s stock is considered to be overbought (>=80).

New Residential Investment’s Stock Yearly Top and Bottom Value

New Residential Investment’s stock is valued at $9.09 at 17:33 EST, way under its 52-week high of $11.81 and higher than its 52-week low of $8.98.

New Residential Investment’s Moving Average

New Residential Investment’s worth is way below its 50-day moving average of $10.83 and way under its 200-day moving average of $10.88.

More news about New Residential Investment.

8. DraftKings (DKNG) – -15.5%

DraftKings Inc. is a US-based digital gaming and entertainment company. It offers daily sports and betting opportunities as well as iGaming. The company is involved in designing and developing software that allows for sports betting, casino gaming platforms and products to be sold online or at retail. It distributes its products through a variety of channels including websites, app downloads and digital direct-to-consumer platforms. DraftKings Inc. has its headquarters in Boston, Massachusetts.

NASDAQ ended the session with DraftKings falling 15.5% to $11.07 on Monday, after two successive sessions in a row of losses. NASDAQ dropped 4.68% to $10,809.23, after three consecutive sessions in a row of losses, on what was a very negative trend trading session today.

Volume

Today’s last reported volume for DraftKings is 18282300 which is 22.29% below its average volume of 23527700.

DraftKings’s last close was $13.10, 79.72% below its 52-week high of $64.58.

DraftKings’s Sales

DraftKings’s sales growth is 42.9% for the ongoing quarter and 91.3% for the next. The company’s growth estimates for the present quarter is a negative 5.3% and positive 14.1% for the next.

DraftKings’s Revenue

Year-on-year quarterly revenue growth grew by 46.9%, now sitting on 1.3B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

DraftKings’s stock is considered to be overbought (>=80).

DraftKings’s Stock Yearly Top and Bottom Value

DraftKings’s stock is valued at $11.07 at 17:33 EST, way under its 52-week high of $64.58 and way higher than its 52-week low of $9.77.

DraftKings’s Moving Average

DraftKings’s value is way under its 50-day moving average of $14.66 and way under its 200-day moving average of $29.86.

More news about DraftKings.

9. Clean Energy Fuels (CLNE) – -14.78%

Clean Energy Fuels Corp. supplies natural gas for alternative fuels in vehicle fleets, mostly in Canada and the United States. It supplies natural gas in three forms: compressed natural gas, renewable gas, and liquefied gas. The company also offers maintenance and operation services to private and public vehicle fleet customers stations. The company also builds, maintains, operates and designs fueling stations. It sells natural gas fueling compressors, as well as other equipment used in CNG stations. Additionally, it offers assessment, design and modification services to provide operators with maintenance and service facilities that comply with the code for natural gas vehicles. The company also transports CNG, LNG, through interconnects, procures RNG, and sells RNG. It offers tradable credit, including RNG, conventional natural gas, as well as RNG as vehicle fuel, with Renewable Identification Numbers (RNN) and Low Carbon Fuel Standards credits. Customers can acquire natural gas vehicles and receive federal, state, and local grants and incentives. The company serves heavy-duty trucks, airports and refuse as well as industrial and institutional energy users. The company had approximately 1000 fleet customers and operated approximately 48,000 gas-powered vehicles. It also owned, operated or supplied approximately 560 natural gas fueling stations across 41 US states and Canada. Clean Energy Fuels Corp. is an American corporation that was founded in 2001. Its headquarters are in Newport Beach.

NASDAQ ended the session with Clean Energy Fuels sliding 14.78% to $4.82 on Monday, following the last session’s downward trend. NASDAQ slid 4.68% to $10,809.23, after three successive sessions in a row of losses, on what was a very bearish trend trading session today.

Volume

Today’s last reported volume for Clean Energy Fuels is 4545820 which is 45.99% above its average volume of 3113640.

Clean Energy Fuels’s last close was $5.65, 55.34% below its 52-week high of $12.65.

Clean Energy Fuels’s Sales

Clean Energy Fuels’s sales growth is 34.3% for the ongoing quarter and 35.2% for the next. The company’s growth estimates for the present quarter and the next is a negative 400% and a negative 100%, respectively.

Clean Energy Fuels’s Revenue

Year-on-year quarterly revenue growth grew by 22.6%, now sitting on 255.65M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Clean Energy Fuels’s stock is considered to be overbought (>=80).

Clean Energy Fuels’s Stock Yearly Top and Bottom Value

Clean Energy Fuels’s stock is valued at $4.82 at 17:33 EST, way below its 52-week high of $12.65 and way higher than its 52-week low of $4.02.

Clean Energy Fuels’s Moving Average

Clean Energy Fuels’s value is way below its 50-day moving average of $6.07 and way below its 200-day moving average of $7.08.

More news about Clean Energy Fuels.

10. Berkeley Lights (BLI) – -13.41%

Berkeley Lights, Inc., is a digital cell biologist company that specializes in accelerating and supporting the development of cell-based biotherapeutics. It offers an integrated platform that includes proprietary consumables such as OptoSelect chips, reagent kit kits, automation systems and software for application and workflow. The company serves North America, Europe, Asia Pacific and Europe. Emeryville is the headquarters of this company, which was founded in 2011.

NASDAQ ended the session with Berkeley Lights falling 13.41% to $4.52 on Monday while NASDAQ fell 4.68% to $10,809.23.

Volume

Today’s last reported volume for Berkeley Lights is 992415 which is 5.77% below its average volume of 1053280.

Berkeley Lights’s last close was $4.52, 91.19% under its 52-week high of $51.28.

The company’s growth estimates for the ongoing quarter is a negative 14.8% and positive 6.7% for the next.

Berkeley Lights’s Revenue

Year-on-year quarterly revenue growth grew by 6.6%, now sitting on 85.39M for the twelve trailing months.

Berkeley Lights’s Stock Yearly Top and Bottom Value

Berkeley Lights’s stock is valued at $4.52 at 17:33 EST, way below its 52-week high of $51.28 and way higher than its 52-week low of $3.66.

Berkeley Lights’s Moving Average

Berkeley Lights’s value is way below its 50-day moving average of $5.35 and way under its 200-day moving average of $14.45.

More news about Berkeley Lights.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here